Implicit Bioscience
  • Home
  • Team
  • Discovery
  • R&D
  • Invest
  • News
  • Contact
  • Home
  • Team
  • Discovery
  • R&D
  • Invest
  • News
  • Contact
15 Dec 2020
Implicit Bioscience Company News Permalink

FDA Grants Approval for Heart Attack Trial

Implicit Bioscience December 15, 2020

The US Food and Drug Administration has issued a “Study May Proceed” letter approving the commencement of clinical study with IC14 in patients with the most severe form of heart attack.

Read more

30 Sep 2020
Implicit Bioscience Company News Permalink

Landmark Publication Points to IC14 Target in ALS-MND

Implicit Bioscience September 30, 2020

ALS-MND is our leading clinical program in neurodegeneration; however Parkinson’s and Alzheimer’s disease are also coming into sharp focus with some extraordinary new data directly related to IC14.

Read more

03 Jun 2020
Implicit Bioscience Company News Permalink

FDA approves COVID-19 study

Implicit Bioscience June 3, 2020

On June 3, the US FDA approved an Investigative New Drug (IND) application for IC14 together with remdesivir in 300 COVID-19 patients at risk of acute respiratory distress syndrome (ARDS).

Read more

16 Dec 2019
Implicit Bioscience Company News Permalink

New research links IC14 target to dementia

Implicit Bioscience December 16, 2019

New research published in the world’s leading journal Neurology reports a link between higher levels of an inflammatory marker called sCD14 and a higher risk of developing dementia.

Read more

17 Sep 2019
Implicit Bioscience Company News Permalink

Australian Immunotherapy Selected for Revolutionary US Clinical Trial Platform Debut

Implicit Bioscience September 17, 2019

An Australian immunotherapy drug will receive a huge boost when it is tested with four other new concepts across 54 clinical sites across the USA in a search for an effective treatment for ALS (a motor neuron disease).

Read more

Next
  • Recent News

    • Heart Attack Data Presented In Berlin
    • IC14 featured in Medicine Journal
    • Protected: Implicit Bioscience Investor Briefings
    • Taming the Immune System in COVID-19 and other Serious Diseases
    • 4BC: Interview with Professor Peter Andrews
  • News Updates

  • Contact Us

    Australia
    Level 1, 32 Logan Road, Woolloongabba, QLD 4102
    +61 7 3721 1210

    United States of America
    523 Broadway E., Suite 412, Seattle, WA 98102
    +1 206 462 2261

BUILT WITH ♡ BY H^CK